Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Ask Michael Burke -- Ignore unavailable to you. Want to Upgrade?

To: Knighty Tin who wrote (92924)	11/8/2001 9:27:56 AM
From: JHP	Read Replies (1) \| Respond to of 132070

Key Points From Analyst Meeting! by: smazo_azzo Long-Term Sentiment: Strong Buy 11/07/01 07:52 pm Msg: 44109 of 44127 Mike Deignan started slow talking about the evolution of EECP. The key points in my opinion were. * VASO just received HFCA notice that EECP reimbursement rates will increase 7%, effective 1/1/02. On top of last years 11.4% increase. Most heart treatments are seeing declines in Medicare reimbursement rates. This will help improve Hospital profits and sell machines. * TS3 is selling for $225,000.Sales are increasing and the trend will continue. 27 salesman onboard with a target of 30 to 40 by the end of 2002. A goal of 50 to have complete US coverage in early 2003. * Deigan indicates VASO will soon achieve $40 million dollar in sales based on internal projections. * Vaso estimates they expect to treat 1 million patients for expanded angina alone. In the words of D. Michael Deigan, "That is a lot of beds". The suggestion is that is a lot of sales yet to be realized for Angina alone. * CHF study to be completed this summer with a 6 month patient followup. Results to be submitted to the FDA in December 2002 for review with approval shortly there after if VASO hits pre-agreed targets with the FDA. VASO is the only company with pre-market certification in this multi-billion dollar market. He indicated that FDA approval is likely. * Most patients with CHF also have diabetes and EECP would help both problems. Consideration under way to evaluate EECP in treating stroke victims. * VASO sees it's patent position strenthening since they have PMA-III's for new indications. This prevents other company's from piggybacking off Vaso research for free! ALA Cardiomedics. Also Vaso has started several new studies to incease their footprint. * VASO recently changed their accounting practices to take advantage of favorable tax laws going forward. The change will create tremendous "CASH FLOW" for Vaso with them realizing over $18 million in tax saving's over the next few years according to Deignan. In the short term, this accounting change makes earning's look like they are not increasing when they actually are. * Deignan noted that VASO's revenue per employee ratio was the best in the medical industry. Deigan indicated the company has a sales multiple of about 7. The industry is up about 40. He believes VASO to be under valued. I may have missed a few items since I don't have my notes in front of me. What I liked most was his confidence that the company's sales will keep increasing at a brisk pace. Message Thread [ View ] Ignore this User \| Report Abuse